{"id":"https://openalex.org/W2147679072","doi":"https://doi.org/10.1016/j.jval.2013.08.1272","title":"Cost-Effectiveness Analysis of Rivaroxaban in Secondary Prevention of ACS in Sweden","display_name":"Cost-Effectiveness Analysis of Rivaroxaban in Secondary Prevention of ACS in Sweden","publication_year":2013,"publication_date":"2013-10-22","ids":{"openalex":"https://openalex.org/W2147679072","doi":"https://doi.org/10.1016/j.jval.2013.08.1272","mag":"2147679072"},"language":"en","primary_location":{"id":"doi:10.1016/j.jval.2013.08.1272","doi":"https://doi.org/10.1016/j.jval.2013.08.1272","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2013.08.1272","pdf_url":null,"source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://doi.org/10.1016/j.jval.2013.08.1272","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5021026018","display_name":"Najida Begum","orcid":"https://orcid.org/0000-0001-9186-8267","observed_orcids":["https://orcid.org/0000-0001-9186-8267"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"N. Begum","raw_affiliation_strings":["Pharmerit Ltd., York, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmerit Ltd., York, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111933083","display_name":"BA Van Hout","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B. Van Hout","raw_affiliation_strings":["Pharmerit Ltd., York, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmerit Ltd., York, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"S. Thurston","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Thurston","raw_affiliation_strings":["Pharmerit Ltd., York, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmerit Ltd., York, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061557141","display_name":"Olaf Schoeman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"O. Schoeman","raw_affiliation_strings":["Bayer Pharma AG, Berlin, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bayer Pharma AG, Berlin, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023365434","display_name":"Anina Fraschke","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Fraschke","raw_affiliation_strings":["Bayer AB, Solna, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bayer AB, Solna, Sweden","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5065978967","display_name":"Freek W.A. Verheugt","orcid":"https://orcid.org/0000-0002-5831-6951","observed_orcids":["https://orcid.org/0000-0002-5831-6951","https://orcid.org/0000-0003-0373-0028"]},"institutions":[{"id":"https://openalex.org/I2802934949","display_name":"Radboud University Medical Center","ror":"https://ror.org/05wg1m734","country_code":"NL","type":"funder","lineage":["https://openalex.org/I2802934949"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"F.W.A. Verheugt","raw_affiliation_strings":["University Medical Center St. Radboud, Nijmegen, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Medical Center St. Radboud, Nijmegen, The Netherlands","institution_ids":["https://openalex.org/I2802934949"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4000,"currency":"USD","value_usd":4000},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.21132521,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"16","issue":"7","first_page":"A524","last_page":"A524"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11064","display_name":"Antiplatelet Therapy and Cardiovascular Diseases","score":0.7465999722480774,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11064","display_name":"Antiplatelet Therapy and Cardiovascular Diseases","score":0.7465999722480774,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.1696999967098236,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10193","display_name":"Coronary Interventions and Diagnostics","score":0.03189999982714653,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rivaroxaban","display_name":"rivaroxaban","score":1.0},{"id":"https://openalex.org/keywords/acute-coronary-syndrome","display_name":"acute coronary syndrome","score":0.9079999923706055},{"id":"https://openalex.org/keywords/secondary-prevention","display_name":"secondary prevention","score":0.9990000128746033},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9440000057220459},{"id":"https://openalex.org/keywords/antithrombotic-therapy","display_name":"antithrombotic therapy","score":0.8539999723434448},{"id":"https://openalex.org/keywords/ischemic-heart-disease","display_name":"ischemic heart disease","score":0.9490000009536743},{"id":"https://openalex.org/keywords/sweden","display_name":"Sweden","score":0.31299999356269836}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8308377861976624},{"id":"https://openalex.org/C2778661090","wikidata":"https://www.wikidata.org/wiki/Q420262","display_name":"Rivaroxaban","level":4,"score":0.5431874990463257},{"id":"https://openalex.org/C194828623","wikidata":"https://www.wikidata.org/wiki/Q2861470","display_name":"Emergency medicine","level":1,"score":0.5259575843811035},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.48960739374160767},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.4650992155075073},{"id":"https://openalex.org/C2777698277","wikidata":"https://www.wikidata.org/wiki/Q266018","display_name":"Acute coronary syndrome","level":3,"score":0.4168928563594818},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.29764795303344727},{"id":"https://openalex.org/C500558357","wikidata":"https://www.wikidata.org/wiki/Q12152","display_name":"Myocardial infarction","level":2,"score":0.2198474109172821},{"id":"https://openalex.org/C2776301958","wikidata":"https://www.wikidata.org/wiki/Q407431","display_name":"Warfarin","level":3,"score":0.17600494623184204},{"id":"https://openalex.org/C2779161974","wikidata":"https://www.wikidata.org/wiki/Q815819","display_name":"Atrial fibrillation","level":2,"score":0.1581256091594696},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.jval.2013.08.1272","doi":"https://doi.org/10.1016/j.jval.2013.08.1272","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2013.08.1272","pdf_url":null,"source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.jval.2013.08.1272","doi":"https://doi.org/10.1016/j.jval.2013.08.1272","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2013.08.1272","pdf_url":null,"source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7095940779","https://openalex.org/W747233123","https://openalex.org/W2086615987","https://openalex.org/W1983906866","https://openalex.org/W2811322748","https://openalex.org/W6995893447","https://openalex.org/W2905622271","https://openalex.org/W4319827740","https://openalex.org/W2502407859","https://openalex.org/W1967521037"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2016-06-24T00:00:00"}